Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma
2019 · Molecular Therapy · 156 citations
https://doi.org/10.1016/j.ymthe.2019.04.001
B
Bijan Boldajipour
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
35
Papers
3.9K
Citations
16
h-index
16
i10-index
Bijan Boldajipour is an academic researcher from Lyell Immunopharma (United States). The author has contributed to research in topics: CAR-T cell therapy research & Immunotherapy and Immune Responses & Viral Infectious Diseases and Gene Expression in Insects. The author has an h-index of 16, co-authored 30 publications.
ORCID: 0000-0003-2065-555XPapers by this author
worksDirect control of CAR T cells through small molecule-regulated antibodies
2021 · Nature Communications · 48 citations
https://doi.org/10.1038/s41467-020-20671-6
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
2018 · Scientific Reports · 33 citations
https://doi.org/10.1038/s41598-018-27264-w
Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation
2024 · Scientific Reports · 5 citations
https://doi.org/10.1038/s41598-024-72392-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat